Does TACROLIMUS Cause Hyperparathyroidism secondary? 44 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 44 reports of Hyperparathyroidism secondary have been filed in association with TACROLIMUS (Tacrolimus). This represents 0.1% of all adverse event reports for TACROLIMUS.
44
Reports of Hyperparathyroidism secondary with TACROLIMUS
0.1%
of all TACROLIMUS reports
0
Deaths
40
Hospitalizations
How Dangerous Is Hyperparathyroidism secondary From TACROLIMUS?
Of the 44 reports, 40 (90.9%) required hospitalization.
Is Hyperparathyroidism secondary Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for TACROLIMUS. However, 44 reports have been filed with the FAERS database.
What Other Side Effects Does TACROLIMUS Cause?
Off label use (8,718)
Drug ineffective (6,214)
Product use in unapproved indication (5,057)
Acute kidney injury (4,005)
Transplant rejection (3,526)
Cytomegalovirus infection (3,320)
Covid-19 (3,201)
Drug interaction (2,896)
Diarrhoea (2,854)
Toxicity to various agents (2,845)
What Other Drugs Cause Hyperparathyroidism secondary?
ESOMEPRAZOLE (1,357)
OMEPRAZOLE (1,274)
PANTOPRAZOLE (947)
LANSOPRAZOLE (888)
DEXLANSOPRAZOLE (382)
RABEPRAZOLE (108)
DENOSUMAB (60)
FUROSEMIDE (49)
OMEPRAZOLE\SODIUM BICARBONATE (48)
ESOMEPRAZOLE\NAPROXEN (47)
Which TACROLIMUS Alternatives Have Lower Hyperparathyroidism secondary Risk?
TACROLIMUS vs TACROLIMUS\TACROLIMUS ANHYDROUS
TACROLIMUS vs TADALAFIL
TACROLIMUS vs TAFAMIDIS
TACROLIMUS vs TAFAMIDIS MEGLUMINE
TACROLIMUS vs TAFASITAMAB